New drug DM002 enters first human tests for advanced cancers
NCT ID NCT06751329
First seen Jan 20, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This early-phase study tests a new drug called DM002 in 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by testing low to higher doses in small groups; second, giving that dose to more participants to check safety and see if the cancer shrinks. Participants will have regular visits and follow-ups for about 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Care Wollongong
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Scientia Clinical Research
RECRUITINGRandwick, New South Wales, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Southern Oncology Clinical Research Unit
RECRUITINGAdelaide, South Australia, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Texas, MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73190, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.